IL241586B - Lymphocyte biomarkers for determining clinical response to mesenchymal stromal cell therapy - Google Patents

Lymphocyte biomarkers for determining clinical response to mesenchymal stromal cell therapy

Info

Publication number
IL241586B
IL241586B IL241586A IL24158615A IL241586B IL 241586 B IL241586 B IL 241586B IL 241586 A IL241586 A IL 241586A IL 24158615 A IL24158615 A IL 24158615A IL 241586 B IL241586 B IL 241586B
Authority
IL
Israel
Prior art keywords
mesenschymal
msc
therapy
determining
stromal cells
Prior art date
Application number
IL241586A
Other languages
English (en)
Hebrew (he)
Inventor
De La Rosa Olga
Lombardo Eleuterio
Dalemans Wilfried
Original Assignee
Tigenix Nv
Tigenix S A U
De La Rosa Olga
Lombardo Eleuterio
Dalemans Wilfried
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix Nv, Tigenix S A U, De La Rosa Olga, Lombardo Eleuterio, Dalemans Wilfried filed Critical Tigenix Nv
Publication of IL241586B publication Critical patent/IL241586B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
IL241586A 2013-03-15 2015-09-16 Lymphocyte biomarkers for determining clinical response to mesenchymal stromal cell therapy IL241586B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382091 2013-03-15
PCT/EP2014/055282 WO2014140362A2 (en) 2013-03-15 2014-03-17 Lymphocyte biomarkers for determining the clinical response to cell therapy

Publications (1)

Publication Number Publication Date
IL241586B true IL241586B (en) 2019-02-28

Family

ID=48044710

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241586A IL241586B (en) 2013-03-15 2015-09-16 Lymphocyte biomarkers for determining clinical response to mesenchymal stromal cell therapy

Country Status (13)

Country Link
US (2) US10660920B2 (enExample)
EP (2) EP2972368B1 (enExample)
JP (2) JP6567430B2 (enExample)
AU (2) AU2014230014B2 (enExample)
CA (2) CA3188652A1 (enExample)
DK (1) DK2972368T3 (enExample)
ES (1) ES2748825T3 (enExample)
HU (1) HUE046531T2 (enExample)
IL (1) IL241586B (enExample)
PL (1) PL2972368T3 (enExample)
PT (1) PT2972368T (enExample)
SG (1) SG11201507521UA (enExample)
WO (1) WO2014140362A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
SG10202001007TA (en) 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
ES2748825T3 (es) 2013-03-15 2020-03-18 Tigenix S A U Biomarcadores de linfocitos para determinar la respuesta clínica a la terapia celular
JP6811724B2 (ja) * 2015-04-24 2021-01-13 ティジェニクス エス．エー．ユー． 細胞療法に対する臨床応答を決定するためのバイオマーカー
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
TW201831681A (zh) * 2016-11-11 2018-09-01 美商生命科學公司 使用人類間葉幹細胞以實現細胞性及體液性免疫的方法
JP7628499B2 (ja) * 2019-02-27 2025-02-10 武田薬品工業株式会社 同種異系療法のための改良された幹細胞集団
WO2021207192A1 (en) * 2020-04-08 2021-10-14 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226828B1 (en) * 1999-10-20 2009-12-09 Chugai Seiyaku Kabushiki Kaisha Use of g-csf for inhibiting gvhd
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
EP1871419A4 (en) * 2005-04-22 2009-01-14 Univ Maryland METHOD FOR THE TREATMENT OF TRANSPLANT-AGAINST RECIPIENT DISEASE
WO2012154344A1 (en) * 2011-04-06 2012-11-15 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
ES2748825T3 (es) 2013-03-15 2020-03-18 Tigenix S A U Biomarcadores de linfocitos para determinar la respuesta clínica a la terapia celular

Also Published As

Publication number Publication date
PT2972368T (pt) 2019-10-18
HK1219775A1 (en) 2017-04-13
CA3188652A1 (en) 2014-09-18
JP6883070B2 (ja) 2021-06-09
US11478511B2 (en) 2022-10-25
WO2014140362A3 (en) 2015-04-16
EP2972368A2 (en) 2016-01-20
SG11201507521UA (en) 2015-10-29
US20160067285A1 (en) 2016-03-10
CA2906299A1 (en) 2014-09-18
JP2016516985A (ja) 2016-06-09
HUE046531T2 (hu) 2020-03-30
PL2972368T3 (pl) 2020-03-31
EP3581932A1 (en) 2019-12-18
WO2014140362A2 (en) 2014-09-18
AU2020200807B2 (en) 2021-10-28
AU2014230014A1 (en) 2015-10-29
JP2019215359A (ja) 2019-12-19
AU2020200807A1 (en) 2020-02-20
US10660920B2 (en) 2020-05-26
ES2748825T3 (es) 2020-03-18
AU2014230014B2 (en) 2019-11-14
DK2972368T3 (da) 2019-10-07
EP2972368B1 (en) 2019-07-24
JP6567430B2 (ja) 2019-08-28
US20200261511A1 (en) 2020-08-20
CA2906299C (en) 2023-04-04

Similar Documents

Publication Publication Date Title
SI2946424T1 (sl) Akumulatorska enota za plovilo
SG11201507521UA (en) Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)
DK3461491T3 (da) Forbedret adoptiv celleterapi
EP2946517A4 (en) AVOIDING INTERRUPTIONS IN A SUPPLY CELL
IL245265A0 (en) Antibodies specific for fcrn
PL2784454T3 (pl) Diagnostyka ogniwa obciążnikowego
EP3052943A4 (en) Biomarkers for cell therapy
IL237744A0 (en) Biomarkers for predicting clinical response to glatiramer acetate
EP3066193C0 (en) CELL CULTURE PROCESS
EP2961825A4 (en) STRUCTURE FOR CULTIVATION OF CELLS
EP3058347A4 (en) Photometric measurement cell
HUP1200239A2 (en) Quantitative biomarkers of the erythrocyte membrane
GB2518263B (en) Diamond based electrochemical sensors
EP2950088B8 (en) Electrochemical measurement device
GB201309561D0 (en) Liquid conductivity measurement cell
DK2951552T3 (da) Opfangningsanordning til engangsbrug
GB2517918B (en) Weighing scale system with interface component
IL255243B (en) Biomarkers to determine clinical response to cellular therapy
SG10201802948PA (en) Disposable photometric measurement tip
EP3036542A4 (en) Blood analysis
GB201316131D0 (en) Biomarkers for disease stratification
SG11201508791WA (en) Melt curve analysis
GB201315532D0 (en) Methods for detecting proteins
GB2509938B (en) Biodiesel Processor
HUP1300692A2 (en) Honeycomb connection for hives with improved features

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed